A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety,
tolerability, and pharmacokinetics (PK) of SR-8541A, an ENPP1 inhibitor, administered orally
as a monotherapy in subjects with solid tumors.